HESI Practice Test Pharmacology

Correct Answer: A

Rationale: The practical nurse should explain to the client that glipizide is not an oral form of insulin but an oral hypoglycemic agent. Glipizide works by enhancing pancreatic production of insulin when some beta cell function is present. It is not a replacement for insulin but helps the body produce more insulin. Therefore, it can be used when there is still some beta cell function present, unlike insulin which is used when there is a deficiency of endogenous insulin production.

Correct Answer: A

Rationale: It is crucial to advise the client to discontinue medication one month before planning to become pregnant to prevent potential harm to the fetus. This precaution is essential as certain medications can have adverse effects on the developing baby. By stopping the medication ahead of time, the client can reduce the risk of any complications during pregnancy.

Correct Answer: A

Rationale: The correct potential adverse effect to monitor for when a client with diabetes mellitus type 2 is prescribed glyburide is hypoglycemia. Glyburide can lead to hypoglycemia, particularly in individuals who do not eat regularly, by stimulating the release of insulin from the pancreas, which can lower blood sugar levels. It is crucial for the nurse to monitor for signs and symptoms of hypoglycemia, such as confusion, sweating, and palpitations, to prevent complications and provide timely interventions.

Correct Answer: A

Rationale: The practical nurse should explain to the client that glipizide is not an oral form of insulin but an oral hypoglycemic agent. Glipizide works by enhancing pancreatic production of insulin when some beta cell function is present. It is not a replacement for insulin but helps the body produce more insulin. Therefore, it can be used when there is still some beta cell function present, unlike insulin which is used when there is a deficiency of endogenous insulin production.

Correct Answer: A

Rationale: The correct answer is A: Increased risk of infection. Adalimumab is known to increase the risk of infection due to its immunosuppressive effects. Patients on adalimumab should be closely monitored for signs and symptoms of infection, such as fever, chills, and malaise, and should promptly report any such symptoms to their healthcare provider for further evaluation and management. Monitoring for infection is crucial to prevent serious complications in patients receiving adalimumab therapy.